FDA Grants Accelerated Approval To Novartis's Asciminib For Philadelphia Chromosome-Positive Chronic Myeloid Leukemia; Clinical Trial Shows 25% Major Molecular Response Rate At 24 Weeks Compared To 13% For Bosutinib
FDA Grants Accelerated Approval To Novartis's Asciminib For Philadelphia Chromosome-Positive Chronic Myeloid Leukemia; Clinical Trial Shows 25% Major Molecular Response Rate At 24 Weeks Compared To 13% For Bosutinib
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated